Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KMT2A rearrange |
| Therapy | Revumenib |
| Indication/Tumor Type | B-cell acute lymphoblastic leukemia |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KMT2A rearrange | B-cell acute lymphoblastic leukemia | sensitive | Revumenib | Guideline | Actionable | Revuforj (revumenib) is included in guidelines for patients with relapsed or refractory B-cell acute lymphoblastic leukemia harboring a KMT2A rearrangement (NCCN.org). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| NCCN.org | Full reference... |